--- title: "Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/271653350.md" datetime: "2026-01-06T13:00:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271653350.md) - [en](https://longbridge.com/en/news/271653350.md) - [zh-HK](https://longbridge.com/zh-HK/news/271653350.md) --- > 支持的语言: [English](https://longbridge.com/en/news/271653350.md) | [繁體中文](https://longbridge.com/zh-HK/news/271653350.md) # Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS Akebia Therapeutics Inc. has announced the dosing of the first patient in a Phase 2 clinical trial evaluating praliciguat, an oral, once-daily soluble guanylate cyclase (sGC) stimulator, for the treatment of biopsy-confirmed focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 60 adults with FSGS who are already receiving maximally tolerated doses of an ACE inhibitor or angiotensin receptor blocker. The trial’s primary endpoint is the change from baseline in urine protein-to-creatinine ratio (UPCR) at Week 24. A secondary endpoint will assess the percentage of patients achieving partial remission at Week 24. All participants will receive praliciguat during an additional 24-week open-label extension period. Study results have not yet been presented and will be provided in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620380-en) on January 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### 相关股票 - [Akebia Therap (AKBA.US)](https://longbridge.com/zh-CN/quote/AKBA.US.md) ## 相关资讯与研究 - [Akebia Flat on Kidney Disease Tests](https://longbridge.com/zh-CN/news/271668540.md) - [Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs](https://longbridge.com/zh-CN/news/280807920.md) - [09:46 ETLifeQuotes.com Reveals Best Life Insurance Rates for Multiple Sclerosis (MS) Patients - Our Top Picks for 2026](https://longbridge.com/zh-CN/news/280803318.md) - [](https://longbridge.com/zh-CN/news/280483998.md) - [A Look At SELLAS Life Sciences Group (SLS) Valuation After SLS009 Data And New Equity Offering Plans](https://longbridge.com/zh-CN/news/280865355.md)